Tigecycline Suppresses the Virulence Factors of Multidrug-Resistant Acinetobacter baumannii Allowing Human Neutrophils to Act

References

• Dijkshoorn L, Nemec A, Seifert H. An increasing threat in hospitals: multidrug-resistant Acinetobacter baumannii. Nat Rev Microbiol. 2007;5:939–951. doi:10.1038/nrmicro1789
   PubMed Web of Science ®Google Scholar
• Antunes LC, Visca P, Towner KJ. Acinetobacter baumannii: evolution of a global pathogen. Pathog Dis. 2014;71:292–301. doi:10.1111/2049-632X.12125
   PubMed Web of Science ®Google Scholar
• Rice LB. Federal funding for the study of anti-microbial resistance in nosocomial pathogens: no ESKAPE. J Infect Dis. 2008;197:1079–1081. doi:10.1086/533452
   PubMed Web of Science ®Google Scholar
• Ayoub Moubareck C, Hammoudi Halat D. Insights into Acinetobacter baumannii: a review of microbiological, virulence, and resistance traits in a threatening nosocomial pathogen. Antibiotics. 2020;9:119. doi:10.3390/antibiotics9030119
   Web of Science ®Google Scholar
• Mulani MS, Kamble EE, Kumkar SN, et al. Emerging strategies to combat ESKAPE pathogens in the era of antimicrobial resistance: a review. Front Microbiol. 2019;10:539. doi:10.3389/fmicb.2019.00539
   PubMed Web of Science ®Google Scholar
• Peleg AY, Seifert H, Paterson DL. Acinetobacter baumannii: emergence of a successful pathogen. Clin Microbiol Rev. 2008;21:538–582. doi:10.1128/CMR.00058-07
   PubMed Web of Science ®Google Scholar
• Uppalapati SR, Sett A, Pathania R. The outer membrane proteins OmpA, CarO, and OprD of Acinetobacter baumannii confer a two-pronged defense in facilitating its success as a potent human pathogen. Front Microbiol. 2020;11:589234. doi:10.3389/fmicb.2020.589234
   PubMed Web of Science ®Google Scholar
• Geisinger E, Huo W, Hernandez-Bird J, et al. Acinetobacter baumannii: envelope determinants that control drug resistance, virulence, and surface variability. Annu Rev Microbiol. 2019;73:481–506. doi:10.1146/annurev-micro-020518-115714
   PubMed Web of Science ®Google Scholar
• Kobayashi SD, Malachowa N, DeLeo FR. Neutrophils and bacterial immune evasion. J Innate Immun. 2018;10:432–441. doi:10.1159/000487756
   PubMed Web of Science ®Google Scholar
• Sato Y, Unno Y, Miyazaki C, et al. Multidrug-resistant Acinetobacter baumannii resists reactive oxygen species and survives in macrophages. Sci Rep. 2019;9:17462. doi:10.1038/s41598-019-53846-3
   Web of Science ®Google Scholar
• Russo TA, Luke NR, Beanan JM, et al. The K1 capsular polysaccharide of Acinetobacter baumannii strain 307-0294 is a major virulence factor. Infect Immun. 2010;8:3993–4000. doi:10.1128/IAI.00366-10
   Web of Science ®Google Scholar
• Kamoshida G, Kikuchi-Ueda T, Nishida S, et al. Pathogenic bacterium Acinetobacter baumannii inhibits the formation of neutrophil extracellular traps by suppressing neutrophil adhesion. Front Immunol. 2018;9:178. doi:10.3389/fimmu.2018.00178
   Web of Science ®Google Scholar
• Kamoshida G, Kikuchi-Ueda T, Tansho-Nagakawa S, et al. Acinetobacter baumannii escape from neutrophil extracellular traps (NETs). J Infect Chemother. 2015;1:43–49. doi:10.1016/j.jiac.2014.08.032
   Web of Science ®Google Scholar
• Russo TA, Beanan JM, Olson R, et al. The K1 capsular polysaccharide from Acinetobacter baumannii is a potential therapeutic target via passive immunization. Infect Immun. 2013;81:915–922. doi:10.1128/IAI.01184-12
   PubMed Web of Science ®Google Scholar
• Nielsen TB, Yan J, Luna BM, et al. Monoclonal antibody requires immunomodulation for efficacy against Acinetobacter baumannii infection. J Infect Dis. 2021;224:2133–2147. doi:10.1093/infdis/jiab265
   Web of Science ®Google Scholar
• Talyansky Y, Nielsen TB, Yan J, et al. Capsule carbohydrate structure determines virulence in Acinetobacter baumannii. PLoS Pathog. 2021;17:e1009291. doi:10.1371/journal.ppat.1009291
   Web of Science ®Google Scholar
• Osei Sekyere J, Govinden U, Bester LA, et al. Colistin and tigecycline resistance in carbapenemase-producing Gram-negative bacteria: emerging resistance mechanisms and detection methods. J Appl Microbiol. 2016;121:601–617. doi:10.1111/jam.13169
   PubMed Web of Science ®Google Scholar
• Cai Y, Chai D, Wang R, et al. Colistin resistance of Acinetobacter baumannii: clinical reports, mechanisms and antimicrobial strategies. J Antimicrob Chemother. 2012;67:1607–1615. doi:10.1093/jac/dks084
   PubMed Web of Science ®Google Scholar
• Foong WE, Wilhelm J, Tam HK, et al. Tigecycline efflux in Acinetobacter baumannii is mediated by TetA in synergy with RND-type efflux transporters. J Antimicrob Chemother. 2020;75:1135–1139. doi:10.1093/jac/dkaa015
   Web of Science ®Google Scholar
• Yaghoubi S, Zekiy AO, Krutova M, et al. Tigecycline antibacterial activity, clinical effectiveness, and mechanisms and epidemiology of resistance: narrative review. Eur J Clin Microbiol Infect Dis. 2021;5:1–20.
   Google Scholar
• Skinner C, Zhang G, Patfield S, et al. An in vitro combined antibiotic-antibody treatment eliminates toxicity from Shiga toxin-producing Escherichia coli. Antimicrob Agents Chemother. 2015;59:5435–5444. doi:10.1128/AAC.00763-15
   Web of Science ®Google Scholar
• Sato Y, Unno Y, Ubagai T, et al. Sub-minimum inhibitory concentrations of colistin and polymyxin B promote Acinetobacter baumannii biofilm formation. PLoS One. 2018;13:e0194556. doi:10.1371/journal.pone.0194556
   PubMed Web of Science ®Google Scholar
• Navidifar T, Amin M, Rashno M. Effects of sub-inhibitory concentrations of meropenem and tigecycline on the expression of genes regulating pili, efflux pumps and virulence factors involved in biofilm formation by Acinetobacter baumannii. Infect Drug Resist. 2019;12:1099–1111. doi:10.2147/IDR.S199993
   PubMed Web of Science ®Google Scholar
• La Scola B, Gundi VA, Khamis A, et al. Sequencing of the rpoB gene and flanking spacers for molecular identification of Acinetobacter species. J Clin Microbiol. 2006;44:827–832. doi:10.1128/JCM.44.3.827-832.2006
   PubMed Web of Science ®Google Scholar
• Ubagai T, Sato Y, Kamoshida G, et al. Immunomodulatory gene expression analysis in LPS-stimulated human polymorphonuclear leukocytes treated with antibiotics commonly used for multidrug-resistant strains. Mol Immunol. 2021;129:39–44. doi:10.1016/j.molimm.2020.11.012
   Web of Science ®Google Scholar
• Ono Y, Kunii O, Kobayashi K, et al. Evaluation of opsonophagocytic dysfunctions in severely burned patients by luminol-dependent chemiluminescence. Microbiol Immunol. 1993;37:563–571. doi:10.1111/j.1348-0421.1993.tb01678.x
   Web of Science ®Google Scholar
• Unno Y, Sato Y, Fukuda H, et al. Resolvin E1, but not resolvins E2 and E3, promotes fMLF-induced ROS generation in human neutrophils. FEBS Lett. 2018;592:2706–2715. doi:10.1002/1873-3468.13215
   Web of Science ®Google Scholar
• Mollinedo F. Neutrophil degranulation, plasticity, and cancer metastasis. Trends Immunol. 2019;40:228–242. doi:10.1016/j.it.2019.01.006
   PubMed Web of Science ®Google Scholar
• Qiu H, Kuolee R, Harris G, et al. Role of NADPH phagocyte oxidase in host defense against acute respiratory Acinetobacter baumannii infection in mice. Infect Immun. 2009;77:1015–1021. doi:10.1128/IAI.01029-08
   Web of Science ®Google Scholar
• McKenna E, Mhaonaigh AU, Wubben R, et al. Neutrophils: need for Standardized Nomenclature. Front Immunol. 2021;12:602963. doi:10.3389/fimmu.2021.602963
   Web of Science ®Google Scholar
• Galkina SI, Fedorova NV, Serebryakova MV, et al. Mold alkaloid Cytochalasin D modifies the morphology and secretion of fMLP-, LPS-, or PMA-stimulated neutrophils upon adhesion to fibronectin. Mediators Inflamm. 2017;2017:4308684. doi:10.1155/2017/4308684
   PubMed Web of Science ®Google Scholar
• Sengstock DM, Thyagarajan R, Apalara J, et al. Multidrug-resistant Acinetobacter baumannii: an emerging pathogen among older adults in community hospitals and nursing homes. Clin Infect Dis. 2010;50:1611–1616. doi:10.1086/652759
   PubMed Web of Science ®Google Scholar
• van Faassen H, KuoLee R, Harris G, et al. Neutrophils play an important role in host resistance to respiratory infection with Acinetobacter baumannii in mice. Infect Immun. 2007;75:5597–5608. doi:10.1128/IAI.00762-07
   PubMed Web of Science ®Google Scholar
• Sato Y, Tansho-Nagakawa S, Ubagai T, et al. Analysis of immune responses in Acinetobacter baumannii-infected klotho knockout mice: a mouse model of Acinetobacter baumannii infection in aged hosts. Front Immunol. 2020;11:601614. doi:10.3389/fimmu.2020.601614
   Web of Science ®Google Scholar
• Jovcic B, Novovic K, Dekic S, et al. Colistin resistance in environmental isolates of Acinetobacter baumannii. Microb Drug Resist. 2021;27:328–336. doi:10.1089/mdr.2020.0188
   Web of Science ®Google Scholar
• Kumar S, Anwer R, Azzi A. Virulence potential and treatment options of multidrug-resistant (MDR) Acinetobacter baumannii. Microorganisms. 2021;9:2104. doi:10.3390/microorganisms9102104
   Web of Science ®Google Scholar
• Geisinger E, Isberg RR. Antibiotic modulation of capsular exopolysaccharide and virulence in Acinetobacter baumannii. PLoS Pathog. 2015;11:e1004691. doi:10.1371/journal.ppat.1004691
   PubMed Web of Science ®Google Scholar
• Xu Q, Chen T, Yan B, et al. Dual role of gnaA in antibiotic resistance and virulence in Acinetobacter baumannii. Antimicrob Agents Chemother. 2019;63:e00694–19. doi:10.1128/AAC.00694-19
   PubMed Web of Science ®Google Scholar
• Wyres KL, Cahill SM, Holt KE, et al. Identification of Acinetobacter baumannii loci for capsular polysaccharide (KL) and lipooligosaccharide outer core (OCL) synthesis in genome assemblies using curated reference databases compatible with Kaptive. Microb Genom. 2020;6:e000339.
   PubMed Web of Science ®Google Scholar